Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Raw Materials: 2023-2024

Historic Raw Materials for Seres Therapeutics (MCRB) over the last 1 years, with Jun 2024 value amounting to $4.9 million.

  • Seres Therapeutics' Raw Materials rose 802.01% to $4.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $4.9 million, marking a year-over-year increase of 802.01%. This contributed to the annual value of $4.4 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q2 2024, Seres Therapeutics' Raw Materials is $4.9 million, which was up 16.81% from $4.2 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Raw Materials registered a high of $4.9 million during Q2 2024, and its lowest value of $547,000 during Q2 2023.
  • Its 2-year average for Raw Materials is $3.5 million, with a median of $4.2 million in 2024.
  • Data for Seres Therapeutics' Raw Materials shows a peak YoY spiked of 802.01% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Seres Therapeutics' Raw Materials stood at $4.4 million in 2023, then spiked by 802.01% to $4.9 million in 2024.
  • Its Raw Materials stands at $4.9 million for Q2 2024, versus $4.2 million for Q1 2024 and $4.4 million for Q4 2023.